BELX Pharmaceutical’s grant application “ A Phase I, Open-Label, Dose Escalation and Extension Study to Evaluate the Safety, Tolerability and Preliminary Effects of Oral BEL-X-HG in Patients with Advanced Refractory Solid Malignancies” to Ministry of Economic Affairs’ “A+ Industrial Innovation R&D Program – Fast Track Clinical Track Program” have been approved and awarded with funding support at Nov. 27^th, 2017.

Cancer is the second leading cause of death worldwide. Moreover, the advanced refractory solid malignancy is an unmet medical need because of its high mortality rate and short overall survival time. The company’s leading candidate, botanical new drug BEL-X, have been proven in pre-clinical stage as the potential treatment of advanced refractory solid malignancies. Once verified and approved after clinical trials, BEL-X will be a blockbuster drug to improve cancer patients’ quality of life and prolong their lifespans. It can also fulfill the gap of urgent medical need in cancer treatment. In addition, it could provide a long-term benefit in promoting the development of Taiwan’s biotech industry.

Our phase I clinical study aims at evaluating the safety, tolerability and preliminary effects of BEL-X in patients with advanced refractory solid malignancies, and is expected to complete in the third quarter of 2019. This study well fits the purpose of Ministry of Economic Affairs’ A+ Industrial Innovation R&D Program to assist and to accelerate the product developments in industries. The funding from this program can help to promote the processes of the company’s R&D and clinical applications. We sincerely appreciate the supports from the government of Taiwan.